Key facts
From your data to clinical reality.
The right treatment. The right dose. For every patient.
Recanthia is developing a transcriptomic approach to understand and predict response to breast cancer treatments, starting with immunotherapy. Here is the essential, without reading the whole site.
The principle in 2 minutes
Recanthia on video.
The need, our approach and what we offer R&D teams, told by Maxime Grember. Voice-over in French.
Download the video (MP4) · 2:05
The need
Breast cancer in France.
new cases in 2023. INCa, Panorama des cancers en France 2026
women affected during their lifetime. [E1] Ameli
breast cancer deaths in 2023. [E2] INCa
patients per year: estimated target population for chemo-immunotherapy in high-risk early TNBC (an estimate, not a count of treated patients). [E3] HAS, 2022
without a complete histological response after chemo-immunotherapy: 36% in the KEYNOTE-522 trial. [E4] EMA
Our approach
A predictive signature, before treatment.
Our principle: identify, before treatment, the patients who will truly benefit from immunotherapy — and understand why others do not respond.
- Tumour profile
- Predictive signature
- Adapted treatment
RAID-BREAST project
Two CRCLille teams working together to develop and consolidate BRCA.cRegMap, a transcriptomic platform dedicated to breast cancers, to predict treatment response and relapse, and explain their biological causes.
The offer
A dual approach.
B2B · from 2027
Predictive tools to support your innovations
- Candidate molecules: sensitivity profiles, treatment response, dose-response curves.
- Patients & opportunities: populations concerned, market potential, unmet needs.
- R&D reports: prioritise targets and guide the search for new treatments.
Clinical · by 2031–2032
Decision support for personalised care
- After clinical validation and regulatory steps.
- Today: breast / TNBC, immunotherapy.
- Tomorrow: lung, head & neck and other treatments.
Our value proposition
A triple benefit.
For patients
The right treatment from the start
Avoid an unnecessary treatment and its side effects, save time towards an effective option and involve every patient in her care.
For the health system
Avoidable spending
≈ €170M / year²About €64,000 additional cost per patient on immunotherapy¹. Up to about €170M of potentially avoidable spending per year in France²: every ineffective treatment avoided is a saving for hospitals, health insurance and society.
Beyond breast cancer
A transferable signature
An approach designed to extend to other cancers treated with immunotherapy.
¹ HAS, Keytruda economic opinion – triple-negative breast cancer (2023): cost difference versus chemotherapy alone.
² Estimate: 6,640 eligible patients per year (HAS) × 40% non-responders × €64,475. A potential, not a measured saving.
Roadmap
From B2B services to clinical access.
- 2027
Launch of B2B services.
- 2028
Confront with the clinic: independent cohorts, reproducibility, performance and limits.
- 2029–2030
Studies and regulatory preparation: clinical evaluations, quality, validation of intended applications.
- 2031–2032
Goal: clinical access. Inform treatment decisions and build the reimbursement pathway.
Target timeline, conditional on results, partners and funding.
Team
Two CRCLille teams.
The Cell plasticity and cancer team and the Digital systems and computational cancer team lead the project. Co-founders: Maxime Grember (CEO) and Dr Nathan Horochowska Laneret (CTO).
The flyer
Everything on two pages.
The full flyer, as distributed (in French), to download or share.
Fund · Collaborate · Connect
The means to move forward.
We are raising €1M for 2027–2028: B2B launch and technology maturation. The clinical programme will be funded later. Details are in the flyer and in the funder space.